Nova Leap Health Corp (NLH)Executive Summary
Nova Leap Health is a consolidator of an extremely fragmented space of home care and home health care agencies. Nova Leap buys them at ~5x EBITDA and subsequently improves EBITDA margin. As the company scales its operations, the operating leverage would lead to margin expansion. The stock price has an upside of ~100% in 1 year.
Opportunity
1) Small Cap (50m)
2) Sell side has not discovered it yet
3) Flying under the radar
Nova presently has a $2.1m cash pile and a long term debt of $2.7m, debt was $5.3M in August with a $2.7M cash pile
Business Overview
NLH is home care and home health care services company operating in Vermont, New Hampshire, Massachusetts, Rhode Island, Oklahoma, Ohio, and Nova Scotia. NLH all entered into all these markets (except for Ohio) through M&A transactions.
Home care covers such activities as:
Dementia care
Personal grooming like bathing or getting dressed
Moving around: getting in and out of the bed/shower
Medication reminders
Errands like grocery shopping and picking up prescriptions
Light housekeeping
Meal preparation
Home healthcare covers such activities as:
Skilled nursing
At-home physical therapy
Pain Management
Caring for wounds
Prescription management
Customer Value Proposition
Home care and home healthcare enables senior citizens to stay in their homes even after they cannot live completely on their own. Homecare crates a buffer from when a senior citizen needs to move to a nursing facility
COVID-19 Tailwind
Senior citizens living at nursing facilities suffered greatly from COVID-19. There were instances where a big part of a nursing home’s population got infected by COVID-19. Second, many senior citizens got locked down at nursing facilities and were not able to see family members for very extended periods of time for safety reasons. Needless to say, that was a real hardship.
Thus, I expect that both senior citizens and their families (e.g., children) would be trying to avoid or at least delay moving to a nursing facility as long as possible which would provide strong tailwinds for home care industry and Nova Leap.
M&A Strategy
1. M&A Criteria
Nova Leap has the following acquisition criteria:
1) U.S. and Canada geographic focus
2) Positive EBITDA with strong reputation/brand
3) Normally 5+ year history
4) Opportunities for operational synergies
5) $1M-$15M of Revenues
Nova Leap is going after targets that are too small for private equity players and as a result faces limited competition. The space is very fragmented, and Nova Leap has many potential acquisition targets in front of it.
M&A Playbook and Integration
Nova Leap buys home care businesses that are primarily private pay. After that Nova Leap makes incremental changes at the acquired operations.
First, Nova Leap implements price increases where it is appropriate.
Second, Nova Leap reducea overtime because overtime destroys gross profit margin.
Third, Nova Leap consolidates the back-office functions such as accounting. For example, instead of an accountant looking after one agency, such account working at Nova Leap HQ would be looking after 3 or 4 home care agencies.
Fourth, better scheduling using scheduling software.
Operating Philosophy
CEO Chris Dobbin runs Nova Leap in a very decentralized fashion. Most locations’ leaders have lots of autonomy. HQ are responsible for setting up standards and back office / accounting. Chris Dobbin spends his time heavily on M&A and overseeing the agencies’ leaders.
Unit Economics
The key operating drivers are the number of client service hours and revenue per hour. Revenue per hour has been quite stable and is ~$25.
Cost per hour has also been stable: ~$16.50 - $17.00.
Thus, the profit per hour is ~$8.50 to $9.
Four-Wall Economics and Four-Wall EBITDA
“Four-wall EBITDA” is of course a misnomer because there are no tangible walls to speak of, but the concept still applies. I want to analyze profitability of field operations first and then overlay HQ expenses on top of that. The key issue that Nova Leap is facing today is its small size of field operations vs. HQ. However, with a few more acquisitions and de minimis growth in HQ expenses (see more on this below), the operating leverage would kick in and lead to a disproportionate increase in EBITDA.
In 2019 segment EBITDA margin (e.g., before HQ costs) was 11.88%. However, in 1Q 2020 and 2Q 2020 it was 10.91% and 10.39% respectively due to the COVID-19 impact.
Revenue run-rate (ex-COVID-19) is ~$5M per quarter or ~$20M per year. With ~12% segment EBITDA margin, NLH should be able to generate ~~$2.4M of segment EBITDA. With the EV of ~$19M, the EV/Segment EBITDA is ~7.85x.
HQ Operations
The HQ team based in Halifax is small and includes CEO, CFO, controller, and business development person. This is purely corporate function.
The HQ also has 5 accountants. However, they work with field agencies.
Nova Leap wants to do 4 to 6 M&A transactions a year (there was zero during COVID-19 pandemic so 2020 number would probably be lower than this target). Doing these M&A transactions will not require hiring any more HQ personnel. However, Nova Leap would probably need to hire an accountant for every 3-4 acquisitions (maybe 5).
HQ expenses are ~$280K - $300K per quarter when there are no M&A transactions. Let’s call it $1.2M per year.
Scaling
What the numbers above is mean is that Nova Leap needs to get another $1M of EBITDA to show the strength of its operating model. That would probably require $5M of capital. I expect that it will be done with a very small dilution to existing shareholders.
Valuation and Upside Potential
As I alluded above, current headline multiple of EBITDA is not particularly attractive. However, with getting more scale and proving the model, I would not be surprised if Nova Leap trades at 12x – 14x EBIDA in 1 year could generate a 100% upside
Risks
M&A Integration
M&A integration risks are inherent for any roll up / consolidation strategy and NLH is not exception.
2. Leverage
NLH has ~$2.0M of debt which is a lot given its EBITDA today. If NLH does not grow its EBITDA, its leverage can become an issue.
Catalysts
1. Continuous M&A
2. Operating leverage showing up as the company continues to scale its operations.
Covid19stock
LEXX -- Biotech play trading below just closed $5.25 financing$13.2M mkt cap, 3.5M float. Freshly uplisted to NASDAQ. Closed $11M oversubscribed financing at $5.25 on January 14th and trading at discount at $4.40. Oversold on the daily (RSI @ 28). Accum/Dist is evening out after 3 days of selloff. Gap at 6.41. Cash + assets exceed current market cap.
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine DevelopmentGeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development
announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19.
The Phase 1 grant, titled, “Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,” will support the ongoing design, construction and preclinical testing of GeoVax’s vaccine candidates in preparation for human clinical trials. The efficacy testing will be performed in collaboration with the University of Texas Medical Branch (UTMB).
Vaccines using the GV-MVA-VLP platform developed for other pathogens have proven to be efficacious with a single dose, having strong durability which would be a significant advantage for SARS-CoV-2 global vaccination campaigns.”
We are pleased to receive this Phase 1 SBIR funding award, which will supplement the internal resources allocated to our COVID-19 vaccine program and accelerate our progress toward human clinical trials.
finance.yahoo.com
Has Zoom Lost its Zip?If any stock defined the age of Covid, it would be Zoom Video Communications. Now the videoconferencing disrupter could be showing that sentiment has truly moved on.
ZM has steadily trended lower since peaking near $590 on October 19. It fell on the November 9 vaccine news, and again December 1 -- despite a very strong quarterly report the night before.
ZM is now clinging to an early-September support level around $350. It could be a make-or-break level, with risk of further selling if it fails.
TradeStation data showed that call volume is down by about half since early December. (From about 147,000 calls per day to just 73,000.) That’s another sign of interest waning in the name.
Finally, valuations remain abnormally high -- even after its 40 percent drop. ZM's price/earnings is about 230 times and price/sales is more than 50 to 1.
(This chart features our Smart Relative Strength custom script.)
TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
MRNA Moderna Hello receive a cordial greeting, and a thriving 2021 our wishes are that 2021 will be a fantastic year in all aspects for all people.
We believe that this action has a great bullish journey based on Technical and Fundamental Analysis
In the short term adjust your stops as it remains in a bearish structure, butv for the medium term has good bullish goals.
Greetings and best wishes for 2021 L.E.D
In Spain as of 12/31/2020
AMZNHello receive a cordial greeting, and a thriving 2021 our wishes are that 2021 will be a fantastic year in all aspects for all people.
A business that behaved very well in 2020, online sales, this amazon case. And everything related to home service online entertainment...
Amazon
supports: 3099 , 2965
Resistors: 3360 ,3491 ,3541
Sincerely L.E.D. In Spain at 30/12/2020
Amazon AMZNHello receive a cordial greeting, and a thriving 2021 our wishes are that 2021 will be a fantastic year in all aspects for all people.
A business that behaved very well in 2020, online sales, this amazon case. And everything related to home service online entertainment...
Amazon
supports: 3099 , 2965
Resistors: 3360 ,3491 ,3541
Sincerely L.E.D. In Spain at 30/12/2020
US500 S&P500 SPY Bull market 15 MINS TODAY, important tomorrow ; SUPPORT 3725
FOR LIGHT MORNING CORRECTION AND RISE TOUCHING RESISTANCE 3737
Hello, can you help me?
I started to worry about the world of trading in January 2020 and shortly after when the pandemic started and we were confined it was a very useful and interesting hobby. Since the pandemic began and with the confinement, I took courses on the stock market, I read, searched, informed, understood and learned a lot.
MANY have earned with platforms like Robinhood ... big amounts of money and that's great but watch out, don't underestimate financial intelligence.
From May 2020 until today I have published 65 investment ideas and before this shitty year is over I will reach 100
Thank you for your time share and support
L.E.D SPAIN 29/12/2020
US500 Bull market 1H
Hello, can you help me?
I started to worry about the world of trading in January 2020 and shortly after when the pandemic started and we were confined it was a very useful and interesting hobby. Since the pandemic began and with the confinement, I took courses on the stock market, I read, searched, informed, understood and learned a lot.
MANY have earned with platforms like Robinhood ... big amounts of money and that's great but watch out, don't underestimate financial intelligence.
From May 2020 until today I have published 65 investment ideas and before this shitty year is over I will reach 100
Thank you for your time share and support
L.E.D SPAIN 29/12/2020
US500 S&P500 Bull market Hello, can you help me?
I started to worry about the world of trading in January 2020 and shortly after when the pandemic started and we were confined it was a very useful and interesting hobby. Since the pandemic began and with the confinement, I took courses on the stock market, I read, searched, informed, understood and learned a lot.
MANY have earned with platforms like Robinhood ... big amounts of money and that's great but watch out, don't underestimate financial intelligence.
From May 2020 until today I have published 65 investment ideas and before this shitty year is over I will reach 100
Thank you for your time share and support
L.E.D SPAIN 29/12/2020
PEIX vs Ethanol Futures (Chicago)Pacific Ethanol doing a reversal up with COVID spike and Ethanol Futures change. Awaiting this going to target $10-11 on short term with another positive earnings and 3rd plant running more to market need. Announcement also selling into more profitable libations market of low calorie seltzers and other consumer driven markets of STAY AT HOME during COVID-19.
Second Wave of Covid-19If there is an second Virus, which is an diffrent variant of Covid-19, then we will see an drop down to 11000 points for sure.
All the Vaccine hype will be over.
Stay safe!
If not, we will have an stop near to us, but if the yellow line will broke it will go down to the next green line, if this can´t hold drop to the next and so on.
KNR.C -- Inverse Head & Shoulders Breakout!Classic Inverse Head & Shoulders breakout on good volume. 4.16 about to get filled and likely $5+ coming before the week's end. Promo campaign is under way and news of sales and/or uplisting to TSX/NASDAQ is expected.
Power Up WorldWith the Vaccine soon to be Online this Chart is looking Fantastic. Covid Has put a Hurting on mines and production is gonna be in Full demand The worlds Power plant are in Great need Uranium.
So with some Volume Short term and long term Macro Chart Look like they are Warming up double Bottom cup Formation Handel to Lift off like to enter somewhere near 12.60 on volume
MRNA Blow Off Top ConfirmedMRNA broke out of $100 hitting $178 within 4 days on high volume and multiple gap ups. This is significant evidence of a blow off top. Afterwards, we printed a daily bullish engulfing pattern then corrected upwards for 5 days before printing another daily engulfing pattern. The target is $100, which completes the blow off top move and the 1.618 extension of the Wave A move. Blow off tops have sharp moves and just as sharp reversals. I'd expect to see $100 by next week.
Vaccibody $VACC leaping to ATH after releasing #Covid19 Data Vaccibody reports promising preclinical data with a second-generation COVID-19 vaccine and announces its infectious disease strategy
● Vaccibody demonstrates promising pre-clinical data with its second-generation COVID-19 vaccine candidate, VB10.COV2
● VB10.COV2 induces rapid, strong and long-lasting neutralizing antibodies and multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell responses in mice after a single dose
● Vaccibody will present the pre-clinical data and its broader infectious disease strategy during a webcast on Friday December 11 at 10 am CET